AstraZeneca stock, pharmaceuticals

AstraZeneca stock slips 1.91 percent as earnings estimates rise

Published on 09/25/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock posted second-quarter revenue of USD 15.38 billion and adjusted expectations now point to FY2026 EPS of USD 10.34. Its LSE range spans GBp 10,524.00 to GBp 15,730.00.

Fotorealistisches Pharmaforschungslabor mit Wissenschaftlern in weißen Kitteln an Mikroskopen und Analysegeräten bei hellem klinischen Licht
AstraZeneca US6549022043 zeigt modernes Pharma Forschungslabor mit Wissenschaftlern an Mikroskopen und Analysegeräten, Illustration mit AI erstellt.

AstraZeneca stock stood at GBp 12,430.00 on the LSE on September 24, 2026, down 1.91 percent from GBp 12,672.00. The move came as earnings expectations were revised higher, with Erste Group Bank raising its FY2026 EPS forecast to USD 10.34 from USD 10.17, according to MarketBeat.

Quarterly earnings beat consensus

AstraZeneca's second-quarter 2026 revenue rose 6.4 percent year over year to USD 15.38 billion, while oncology revenue increased 18 percent in the first half to USD 14.12 billion, according to Yahoo Finance.

Quarterly EPS came in at USD 2.63 versus a USD 2.50 consensus estimate, a USD 0.13 beat. The same result was USD 0.46 above the USD 2.17 EPS reported for the comparable quarter, according to MarketBeat.

Estimates rise despite pipeline risk

Erste Group Bank also lifted its FY2027 EPS forecast to USD 11.50 from USD 11.44. Its FY2026 estimate stands USD 1.00 above the cited USD 9.34 consensus, creating a concrete gap between one bank's view and the broader forecast, MarketBeat reported.

The counterweight is clinical execution. AstraZeneca's camizestrant missed the primary endpoint in the Phase III SERENA-4 trial, which enrolled 1,371 patients, according to Yahoo Finance. That result matters because oncology generated USD 14.12 billion in the first half, making pipeline delivery central to the growth case.

Stock stays below yearly high

The LSE quote remains between a 52-week low of GBp 10,524.00 and a high of GBp 15,730.00 as of September 24, 2026. AstraZeneca's market capitalization was USD 255,211,570,866 as of September 25, 2026, while the company's investor-relations calendar lists a September 29, 2026 virtual Santander Pharma Day.

AstraZeneca stock facts

  • Company: AstraZeneca PLC
  • Ticker: AZN
  • Trading venue: London Stock Exchange
  • Price as of September 24, 2026: GBp 12,430.00
  • Market capitalization: USD 255,211,570,866 as of September 25, 2026
  • 52-week range: GBp 10,524.00-GBp 15,730.00
  • Sector / Industry: Health care / Pharmaceuticals
  • Index membership: FTSE 100

Disclaimer...

en | boerse | 70182646 |